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Abstract
Background The prospective WEARIT-II-EUROPE registry aimed to assess the value of the wearable cardioverter-defi-
brillator (WCD) prior to potential ICD implantation in patients with heart failure and reduced ejection fraction considered 
at risk of sudden arrhythmic death.
Methods and results 781 patients (77% men; mean age 59.3 ± 13.4 years) with heart failure and reduced left ventricular 
ejection fraction (LVEF) were consecutively enrolled. All patients received a WCD. Follow-up time for all patients was 
12 months. Mean baseline LVEF was 26.9%. Mean WCD wearing time was 75 ± 47.7 days, mean daily WCD use 20.3 ± 4.6 h. 
WCD shocks terminated 13 VT/VF events in ten patients (1.3%). Two patients died during WCD prescription of non-
arrhythmic cause. Mean LVEF increased from 26.9 to 36.3% at the end of WCD prescription (p < 0.01). After WCD use, 
ICDs were implanted in only 289 patients (37%). Forty patients (5.1%) died during follow-up. Five patients (1.7%) died with 
ICDs implanted, 33 patients (7%) had no ICD (no information on ICD in two patients). The majority of patients (75%) with 
the follow-up of 12 months after WCD prescription died from heart failure (15 patients) and non-cardiac death (15 patients). 
Only three patients (7%) died suddenly. In seven patients, the cause of death remained unknown.
Conclusions Mortality after WCD prescription was mainly driven by heart failure and non-cardiovascular death. In patients 
with HFrEF and a potential risk of sudden arrhythmic death, WCD protected observation of LVEF progression and appraisal 
of competing risks of potential non-arrhythmic death may enable improved selection for beneficial ICD implantation.
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• Mean wear me 75 days 
• Mean daily WCD use 20.3h 
• 13 VT/VF events in 10 paents 



























12 months follow-up 
Phase 1 Phase 2 
40 deaths (5%) 
heart failure 
mode of death 
n=4 n=10 n=1 
sudden death 
n=0 n=3 n=0 
non-cardiac death 
n=1 n=14 n=0 
unknown 
n=0 n=6 n=1 
ICD (+) 
n=5 




Keywords Heart failure · Sudden cardiac death · Implantable cardioverter-defibrillator · Wearable cardioverter-defibrillator
Introduction
Numerous randomized trials have proven the benefit of pri-
mary prevention cardioverter-defibrillator (ICD) implanta-
tion. Currently, assumption of a life-threatening arrhythmic 
risk is almost exclusively based on reduced left ventricu-
lar ejection fraction (LVEF ≤ 35%) and clinical symptoms 
of heart failure [1]. Conditions or causes of an increased 
arrhythmic risk may change over time, and the threat of 
an arrhythmic death may lower or no longer exists [2]. 
Although the wearable cardioverter-defibrillator (WCD) has 
been introduced into clinical practice more than 15 years 
ago, general acceptance of this device for risk assessment 
is still limited [3–8]. Use of the WCD seems to be a suit-
able approach to perform protected risk assessment until 
the decision to either implant or withhold an ICD for pri-
mary prevention. Recently, the WEARIT-II-US registry has 
demonstrated that life-threatening arrhythmic events dur-
ing the time of WCD wearing can reliably be terminated by 
shock delivery [9]. In contrast to WEARIT-II-US and other 
previous registries, the objective of the current WEARIT-
II-EUROPE registry was to demonstrate the clinical value 
of the WCD prescription in patients with heart failure and 
reduced ejection fraction (HFrEF) prior to deciding for or 
against primary preventive ICD implantation. During the 
time of WCD prescription, physicians had the opportunity 
to monitor patients’ ECG, to assess the improvement of car-
diac function and to appraise patients’ overall mortality risk 
and particularly the likelihood of arrhythmic death. The cur-
rent registry uniquely included a 1-year follow-up after the 
WCD prescription period to analyze the clinical outcome 
and mode of death.
To increase the benefit of primary prevention ICD ther-
apy, we hypothesize that protected risk assessment prior to 
potential ICD implantation can effectively be performed 
under the umbrella of the WCD.
Methods
The WEARIT-II-EUROPE registry is a prospective, multi-
center, observational registry of patients to whom the WCD 
was prescribed in 30 German tertiary clinical centers during 
a time period of 21 months (January 2014–September 2015). 
All enrolled patients had a potential risk of life-threatening 
ventricular arrhythmias. Prescription of the WCD, its wear-
ing time and therapy thereafter were left to the discretion of 
the attending physicians.
The registry consisted of two phases: Phase 1 of the reg-
istry started after patients’ signed consent with prescrip-
tion of the WCD and ended with termination of WCD pre-
scription. Phase 2 started after WCD prescription up to a 
follow-up of 12 months after WCD prescription. At WCD 
prescription, patients were categorized into specific groups 
of pre-specified WCD indications: (1) newly diagnosed non-
ischemic cardiomyopathy (NICM) with reduced LV function 
(LVEF ≤ 35%) including myocarditis, cardiac sarcoidosis, 
peripartum cardiomyopathy, or idiopathic cardiomyopathy; 
(2) new hospitalization for acute heart failure (HF) with 
structural heart disease regardless of the underlying etiology; 
104 Clinical Research in Cardiology (2021) 110:102–113
1 3
(3) severely reduced LVEF (≤ 35%) within the first week 
following acute myocardial infarction (AMI), independent 
of performed revascularization (PCI) or early occurring VT/
VF events; (4) reduced LV function (LVEF ≤ 35%) less than 
1 month after elective PCI procedures or recent coronary 
artery bypass grafting (CABG); and (5) other risk assess-
ment indications with or without structural heart disease in 
the presence of non-sustained ventricular tachycardia, ECG 
abnormalities, unexplained syncope or aborted cardiac arrest 
of unknown cause, including patients with presumed inher-
ited arrhythmia disorders.
During Phase 2 of the registry, all major clinical events, 
LVEF re-assessment, ICD implantation, shock delivery, and 
ICD complications were recorded.
The main objectives of the registry were to investigate the 
clinical course after prescription of the WCD with respect 
to improvement of left ventricular function (LVEF) under 
guideline-directed medical therapy (GDMT) and overall 
mortality at 12 months after WCD prescription.
All clinical data and events were stored in an electronic 
CRF system. The registry protocol was approved by the Cen-
tral Ethical Committee Board (IRB) of the State of Bavaria, 
Germany, and the ethical committee boards of each partici-
pating center. All patients gave written informed consent.
Arrhythmic events during WCD prescription
Centers had continuous access to patients’ ECG and WCD 
wearing compliance via telemonitoring (LifeVest  Network®, 
ZOLL-Inc. Pittsburgh, USA). Recorded WCD events were 
classified as true arrhythmic events or artifacts. Any arrhyth-
mia episode, separated by at least 30 min from a previous 
episode, was considered an independent arrhythmic event. 
Arrhythmic events were classified as either potentially life-
threatening or non-life-threatening events. Life-threatening 
episodes were ventricular fibrillation (VF), and sustained 
ventricular tachycardia (VT) (> 30 s). Non-life-threatening 
arrhythmia episodes were non-sustained VT, paroxysmal 
or persistent atrial fibrillation, atrial flutter, or any regu-
lar supraventricular tachycardia (SVT). Separately, severe 
bradycardia (< 20 bpm) or asystole were adjudicated as 
bradycardia events. WCD shocks delivered for non-life-
threatening events were considered as inappropriate. Use 
of WCD response buttons for arrhythmic events was also 
analyzed. WCD data and all arrhythmic events were blindly 
reviewed by one of the authors (HUK).
Statistical analysis
Continuous variables are reported as mean/median with 
interquartile ranges. Categorical data are reported as fre-
quencies and percentages. Groups were compared using 
Student’s t test for testing differences in continuous variable 
LVEF points from different time points: inclusion, Phase 
1 and Phase 2 and Pearson’s chi-square test for testing the 
independency of categorical variables LV-EF group/NYHA 
and the clinical phase as appropriate. The cumulative inci-
dence of arrhythmic events and time to first life-threatening 
VT/VF event are displayed using the Kaplan–Meier method. 
Similarly, cumulative survival with or without ICD implan-
tation was analyzed. Cox proportional hazards regression 
models were assessed on age groups, LVEF categories, dif-
ferent WCD indications and a stepwise variable selection 
was performed on the models. Statistical tests were per-
formed 2-sided and nominal p values of < 0.05 were consid-
ered statistically significant. Analyses were performed with 
R project for statistical computing (version 3.0.2 or later).
Results
Patient population
The WEARIT-II-EUROPE registry enrolled 892 patients; 
two patients withdrew permission to use their personal data 
prior to WCD activation, and five patients were considered 
not suitable for WCD wearing. Therefore, the registry pop-
ulation consisted of 885 patients (Fig. 1). A total of 104 
patients were excluded from this current analysis since they 
already had an established ICD indication. In 63 patients, the 
WCD was prescribed after ICD removal and in 41 patients 
ICD implantation was postponed due to comorbidities.
The remaining 781 patients without already confirmed 
ICD indication were analyzed. Patient baseline character-
istics and indications for WCD prescription are shown in 
Table 1. 599 men (77%) and 182 (23%) women were enrolled 
with a mean age of 59.3 ± 13.4 years. Patients were catego-
rized according to the WCD prescription. In 249 patients 
Fig. 1  Flow chart of the WEARIT-II-EUROPE registry
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(32%), the WCD was prescribed because of newly diagnosed 
non-ischemic cardiomyopathy; in 230 patients (30%) hos-
pitalized with newly diagnosed acute heart failure; in 128 
patients (16%) immediately (< 1 week) after acute myocar-
dial infarction with LVEF ≤ 35%; in 72 patients (9%) who 
underwent revascularization procedures without concomi-
tant acute myocardial infarction; and in 102 patients (13%) 
for various reasons (unknown causes of syncope, aborted 
cardiac arrest or presumed inherited arrhythmia syndromes).
Phase I: WCD prescription period
Mean WCD prescription time of the total patient cohort was 
75.0 ± 47.7 days (interquartile range 45–93 days); while, 
the mean daily usage was 20.3 ± 4.6 h (interquartile range 
19.5–23.2 h). Arrhythmic events during WCD prescription 
are shown in Table 2. Ten patients (1.3%) received appro-
priate shocks for 13 VT/VF episodes. Every sustained VT/
VF event was terminated with a single WCD shock. Two 
patients (0.3%) received a single inappropriate shock for 
rapid atrial fibrillation. Twenty-two patients pressed the 
response buttons of the WCD to withhold shock delivery 
for a total of 47 tachycardia episodes (24 sustained VTs in 
12 patients, and 23 atrial tachyarrhythmias in 10 patients). 
Distribution of VT/VF events within the various WCD indi-
cations is listed in Table 2. No patient had untreatable or 
undetected ventricular arrhythmic events. No bradycardia 
events (< 20 bpm) occurred. During WCD prescription, two 
patients died 17 and 43 days after WCD prescription. One 
patient died from terminal heart failure, the other patient 
from non-cardiac cause (renal failure).
Phase II: Follow‑up period
779 patients finished WCD wearing and entered the Phase 2 
of the registry with a planned follow-up time of 12 months. 
During follow-up, two patients withdrew their permission to 
be followed further and seven patients were lost to follow-up 
(Fig. 1).
After WCD prescription, ICD implantation was per-
formed in 289 of 779 patients (37%); whereas in 472 
patients (61%), ICDs were not implanted. In 18 patients 
(2%), status of ICD implantation is unknown (Table 3). Of 
the 399 patients with LVEF ≤ 35% after WCD prescription, 
251 (63%) received ICDs, but 140 (35%) remained without 
defibrillators; in eight patients (2%), ICD implantation is 
unknown. Of 380 patients with LVEF > 35%, after WCD 
prescription, 38 (13%) received ICDs (Table 4). The major-
ity of those (68.4%) received ICDs due to frequent non-
sustained VTs recorded during WCD prescription without 
shock delivery. In 12 patients, the ICD was implanted after 
further diagnostic work-up during WCD prescription. Five 
patients (13.2%) were finally diagnosed with an inherited 
arrhythmia syndrome and in seven patients (18.4%), the 
ICD was implanted following arrhythmogenic syncope due 
to ventricular tachyarrhythmias. ICD infection and compli-
cations occurred in seven patients, requiring removal of the 
Table 1  Baseline characteristics
BMI Body mass index, CABG Coronary artery bypass grafting, LVEF 
Left ventricular ejection fraction, PCI Percutaneous coronary inter-
vention, WCD Wearable cardioverter-defibrillator
781 patients
Mean age (years) 59.3 ± 13.4
Males 599 (77%)
Mean BMI (kg/m2) 28.2 ± 5.3
Mean LVEF (%) 26.9 ± 10.3
LVEF ≤ 35% 700 (90%)
LVEF > 35% 81 (10%)
WCD indications
 Non-ischemic cardiomyopathy 249 (32%)
 Recent onset/impairment of heart failure 230 (30%)
 Acute myocardial infarction 128 (16%)
 Revascularization procedures (PCI/CABG) 72 (9%)
 Other risk stratification 102 (13%)
WCD wearing time
 Mean wearing time 75.0 ± 47.7 days
 Mean WCD wearing per day 20.3 ± 4.6 h/day
Table 2  Arrhythmic events during WCD wearing
CABG Coronary artery bypass grafting, ICD Implantable cardio-
verter-defibrillator, PCI Percutaneous coronary intervention, SVT 
supraventricular tachyarrhythmia, VF ventricular fibrillation, VT ven-
tricular tachycardia, WCD wearable cardioverter-defibrillator
Patients (n) Events (n)
Total 781 83
WCD shocks 12 (1.5%) 15
 Appropriate shocks 10 (1.3%) 13
 Inappropriate shocks 2 (0.3%) 2
Ventricular tachyarrhythmias 21 (2.7%) 37
 Response button use for VT/VF 12 (1.5%) 24
WCD indications
 Non-ischemic cardiomyopathy (n = 249) 6 (2.4%) 15
 Heart failure hospitalization (n = 230) 3 (1.3%) 4
 Acute myocardial infarction (n = 128) 6 (4.6%) 10
 Post PCI/cardiac surgery (CABG) (n = 72) 3 (4.2%) 4
 Other risk assessment (n = 102) 3 (2.9%) 4
Supraventricular tachyarrhythmias 18 (2.3%) 46
 Atrial fibrillation/atrial flutter 12 (1.5%) 38
 Supraventricular tachycardia 6 (0.8%) 8
 Response button use for SVT 10 (1.3%) 23
Bradycardia/asystole 1 (0.1%) 1
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device in five. During follow-up, 12 out of 289 ICD patients 
(4%) received appropriate ICD therapies for VT/VF events.
During phase II follow-up, 40 of 770 patients (5.1%) died. 
The mode of death was classified as sudden cardiac death 
in three patients (0.4%); 15 patients (1.9%) died of terminal 
heart failure; 15 patients (1.9%) of non-cardiac death; and in 
seven patients (0.9%), the cause of death remained unknown 
(Table 5). In 27 deaths (67%), LVEF at the end of WCD 
prescription had either decreased or remained unchanged 
compared to baseline LVEF. In 29 deceased patients (72%) 
LVEF after WCD prescription was ≤ 35%. Cumulative sur-
vival during the time of follow-up was significantly better for 
patients in whom LVEF increased > 10% points compared 
to those with decreased, unchanged or even only slightly 
increased LVEF after WCD prescription (Fig. 2).
Of the 472 patients who did not receive ICDs after WCD 
prescription, 33 (7%) patients died during follow-up, ten 
due to heart failure, 14 of non-cardiac death, and three had 
sudden death. In contrast, of 289 patients with implanted 
ICDs, five patients (1.7%) died, four due to heart failure 
and one patient due to non-cardiac death (Fig. 3). Cumula-
tive survival with implanted ICDs after WCD prescription 
was significantly better compared to patients who were left 
without ICD therapy (p = 0.002) (Fig. 4).
Development of left ventricular ejection fraction
Progression of LVEF following WCD prescription up to 
12 months of follow-up was one of the primary objectives 
of WEARIT-II-EUROPE. At baseline, mean LVEF of 781 
patients was 26.9% ± 10.3% and increased to 36.3% ± 12.3% 
after the end of WCD prescription (p < 0.01). LVEF signifi-
cantly increased in all five WCD indication groups (Table 6). 
After the end of WCD prescription, 44% of the cohort with 
an initial LVEF < 35% showed increased LVEF to > 35% 
(Fig. 5). Until 12-month follow-up, LVEF further increased 
to a mean of 39.4% ± 12.8%. After WCD prescription LVEF 
showed further significant increase in patients categorized in 
“non-ischemic cardiomyopathy”, “acute myocardial infarc-
tion” and “heart failure hospitalization”.
Table 3  ICD implantation 
after WCD wearing by WCD 
indication
LVEF left ventricular ejection fraction, WCD wearable cardioverter-defibrillator, PCI percutaneous coro-
nary intervention, CABG coronary artery bypass grafting, ICD implantable cardioverter-defibrillator, AMI 
acute myocardial infarction
WCD indication Mean LVEF after 
WCD wearing
ICD implanted No ICD implanted Missing data
Non-ischemic cardiomyopathy 36.4 ± 12.8% 90 (36%) 153 (62%) 5 (2%)
Hospitalization for heart failure 34.4% ± 11.4% 79 (34%) 142 (62%) 9 (4%)
AMI 35.1 ± 10.4% 42 (33%) 84 (66%) 2 (1%)
PCI/CABG 33.9 ± 10.4% 34 (47%) 37 (51%) 1 (2%)
Other risk assessment 44.1 ± 13.7% 44 (43%) 56 (56%) 1 (1%)
Total (n = 779) 36.3 ± 12.3% 289 (37%) 472 (61%) 18 (2%)
Table 4  ICD implantation according to LVEF after WCD wearing
ICD implantable cardioverter-defibrillator, LVEF left ventricular ejec-
tion fraction, WCD wearable cardioverter-defibrillator
LVEF ≤ 35% LVEF > 35%
ICD implantation 251 (63%) 38 (10%)
No ICD implantation 140 (35%) 332 (87%)
ICD status unknown 8 (2%) 10 (3%)
Total (n = 779) 399 (51%) 380 (49%)
Table 5  Mode of death during 
follow-up after WCD wearing 
(phase 2)
WCD wearable cardioverter-defibrillator, PCI percutaneous coronary intervention, CABG coronary artery 
bypass grafting, ICD implantable cardioverter-defibrillator, AMI acute myocardial infarction
WCD Indication/deaths Sudden 
cardiac 
death
Heart failure death Non-cardiac death Death of 
unknown 
cause
Non-ischemic cardiomyopathy (n = 7) 1 3 1 2
Heart failure hospitalization (n = 9) 1 5 1 2
AMI (n = 11) 0 2 7 2
PCI/CABG (n = 8) 1 3 3 1
Other risk assessment (n = 5) 0 2 3 0
Total (n = 40) 3 (7%) 15 (38%) 15 (38%) 7 (17%)
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Discussion
The WEARIT-II-EUROPE registry is the first large prospec-
tive registry not only analyzing the period of WCD prescrip-
tion but also providing a 12-month follow-up after WCD 
prescription. Thus, the focus of WEARIT-II-EUROPE was 
not the period of WCD prescription but rather the follow-
ing time with respect to improvement of LVEF and overall 
mortality outcome.
The main findings of WEARIT-II-EUROPE are: (1) the 
WCD is protective during risk assessment for ICD indica-
tion. All life-threatening ventricular arrhythmic events were 
effectively terminated by WCD shocks (2) wearing compli-
ance is high. (3) After newly diagnosed heart failure, LVEF 
improves significantly during WCD prescription and up to 
12 months thereafter. (4) Primary preventive ICD implan-
tation was withheld in 35% of patients, despite severely 
reduced LVEF. (5) Heart failure death and non-cardiac death 
were the main causes of death at 12-month follow-up.
WCD period
WCD prescription was an inclusion criterion of WEARIT-
II-EUROPE. In contrast to WEARIT US and other WCD 
registries, the main objective of WEARIT-II-EUROPE was 
not just the assessment of potential ventricular arrhythmias. 
The WCD was particularly prescribed to provide a protected 
period for optimization of GDMT and better risk assessment 
for potential future ICD implantation.
In WEARIT-II-EUROPE, wear-time compliance with 
more than 20  h per day was consistent with previous 
Fig. 2  Cumulative survival 
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Death of unknown cause
Fig. 3  Mode of death according to ICD status
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published registries [9–11]. The incidence of ventricular 
tachyarrhythmia events within the different patient cohorts 
was comparable with other studies and varied from 1.3 to 
4.7% within a mean of 75 ± 47.7 days WCD wearing [10, 
12, 13]. The majority of VT/VF events occurred in heart 
failure with ischemic etiology. The VT/VF event rate con-
firms the results of the prospective VEST-trial and other 
WCD registries [11, 14]. It is important to observe that 
only ten out of 21 VT/VF events needed termination by 
WCD shocks. In 52% of these events, WCD shocks were 
withheld by use of the response button. This indicates that 
half of the VT/VF events were hemodynamically stable, 
tolerated by the patient and terminated spontaneously 
within minutes. In WEARIT-II-EUROPE, no ineffective 
shock delivery occurred, and the incidence of inappropri-
ate shocks (0.3%) was tolerably low. Previously unknown 
supraventricular tachyarrhythmias were detected in 2.3% 
of the patients. All in all, the WCD effectively protected 
patients from sudden arrhythmic death and detected 
clinically significant new arrhythmias in a total of 3.7% 
of the patients.
Development of left ventricular function
During a mean WCD prescription of 75 days allowing opti-
mization of GDMT, mean LVEF significantly increased in 
all five WCD indication categories (Table 6). Overall, in 
44% of all patients, LVEF was higher than 35% at the end 
of WCD prescription, making ICD implantation redundant 
or at least not guideline indicated. Of the 51% of patients 
with a baseline LVEF ≤ 25%, only 22% continued to have 
a LVEF < 35%.
Time and adequate dosage of medication are the main 
factors for LVEF recovery [11, 15–17]. Especially in patients 
with “non-ischemic cardiomyopathy”, “hospitalization for 
newly diagnosed acute heart failure” and “acute myocardial 
infarction”, waiting time plays a major role for LVEF recov-
ery. It is important to note that in these WCD categories, 
Fig. 4  Cumulative survival 
according to ICD implantation 
following WCD prescription
Table 6  Development of left ventricular ejection fraction baseline, after phase 1 and after phase 2
CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, PCI percutaneous coronary intervention, WCD wearable cardio-
verter-defibrillator
WCD indication LVEF baseline (%) LVEF after 
phase 1 (%)









Non-ischemic cardiomyopathy 26.1 ± 10.4 36.4 ± 12.8 < 0.01 40.7 ± 12.4 < 0.01 < 0.01
Heart failure hospitalization 23.6 ± 7.5 34.4 ± 11.4 < 0.01 38.1 ± 13.7 < 0.01 < 0.01
Acute myocardial infarction 26.7 ± 6.6 35.1 ± 10.4 < 0.01 37.6 ± 11.4 < 0.01 < 0.01
Revascularization PCI/CABG 25.7 ± 5.9 33.9 ± 10.4 < 0.01 35.8 ± 11.2 ns < 0.01
Other risk stratification 38.3 ± 14.3 44.1 ± 13.7 < 0.01 44.1 ± 13.4 ns < 0.01
Total 26.9 ± 10.3 36.3 ± 12.3 < 0.01 39.4 ± 12.8 < 0.01 < 0.01
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further significant increase of LVEF up to 12 months was 
observed compared to end of WCD prescription. These find-
ings indicate that reverse remodeling needs time and is not 
completed within the first 2–3 months after heart failure 
diagnosis. Obviously, more time is needed to evaluate the 
effect of GDMT on reverse remodeling and heart failure 
symptoms [18]. Re-assessment of LVEF after the provided 
time of therapy adjustment is of imminent importance for the 
appraisal of patients’ overall outcome and for confirmation 
or deferring of ICD implantation [19–21].
WEARIT-II-EUROPE demonstrates that patients with 
decreased or unchanged LVEF after WCD prescription have 
a significantly lower 12-month survival than patients show-
ing more than 10% increase of their LVEF (Fig. 3). Other 
studies have dearly shown that awaiting LVEF recovery is of 
great importance [22]. The PREDICTS study assessed inde-
pendent clinical parameters that predicted significant LVEF 
recovery to greater than 35% after 3 months in patients after 
acute myocardial infarction with initial LVEF ≤ 35% [23]. 
The authors showed that their risk score model identified 
LVEF recovery beyond 35% in 57% of their patient cohort. 
Another study of a large patient cohort showed that patients 
with heart failure and recovery from preexisting reduced 
LVEF had a lower overall mortality and less frequent 
hospitalizations than patients with higher but stable pre-
served LVEF [24]. This indicates that recovery of initially 
reduced LVEF may be more advantageous and is a better 
predictor for a favorable overall outcome compared to ini-
tially higher but unchanging LVEF [25]. An earlier study 
in patients with non-ischemic cardiomyopathy found better 
overall outcome with recovered LVEF and appropriate heart 
failure therapy compared to those with preexisting higher 
LVEF and less heart failure symptoms [26]. Our findings 
confirm results from the PROLONG study indicating that 
waiting beyond 3 months after heart failure diagnosis may 
have a beneficial impact on ICD implantation decisions due 
to continued reverse remodeling of LV function [11].
Mortality and prognosis following WCD period
WEARIT-II-EUROPE is the first registry providing pro-
spective data on mortality after WCD prescription in a 
large patient population including assessment of the mode 
of death with and without ICD implantation.
At the end of WCD prescription, a total of 51% showed a 
LVEF ≤ 35%. Physicians rejected ICD implantation in 140 
patients, although LVEF was measured below 35% after 
WCD prescription. This demonstrates that the decision for 
Fig. 5  Distribution of LVEF 
at baseline (a) and at the end 
of Phase 1 (b) after initiation 
and optimization of guideline-
directed heart failure medication 
during WCD prescription
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ICD implantation was not solely depending on measurement 
of LVEF progression but was guided by the general status 
of patients’ disease process or their expected overall sur-
vival. Patients who remained without ICDs showed signifi-
cantly higher overall mortality (7%) after 1 year compared 
to patients in whom ICDs were implanted (1.7%). However, 
the cause of death in patients without ICDs was unrelated 
to arrhythmic events in at least 73% of all patients. These 
patients died due to heart failure progression or non-cardi-
ovascular cause, an ICD cannot prevent. In ICD receivers 
all deaths occurred within 9 months post implantation due 
to heart failure progression or non-cardiovascular causes. 
Thus, the results of WEARIT-II-EUROPE strongly support 
the requirement of individual risk assessment beyond LVEF 
measurement prior to ICD implantation with the option to 
reject defibrillator therapy if patients’ condition, co-morbid-
ity and general condition vote against beneficial ICD therapy 
[27].
Overall mortality after WCD prescription in WEARIT-
II-EUROPE was 5.2%. One-year mortality differed between 
etiologies of heart failure. Worst prognosis was observed in 
patients with an ischemic cardiomyopathy (acute MI and 
post-revascularization with severely reduced left ventricular 
function). Overall mortality in this population was 9.5%. 
Patients with non-ischemic cardiomyopathy had the best 
prognosis (1-year mortality 3.6%). Heart failure death and 
non-cardiac causes were the dominant modes of death. In 
WEARIT-II US, 1-year mortality in patients with ischemic 
etiology was only 3% (with implanted ICDs) and 4% (with-
out ICDs). Mortality in non-ischemic cardiomyopathy (3%) 
was similar in the two WEARIT registries [28]. Mode of 
death during follow-up was not assessed in WEARIT-II-US 
registry. Thus, differences of mortality between Europe and 
the USA cannot be sufficiently explained.
Two important trials have shown that early ICD implanta-
tion after acute myocardial infarction did not provide long-
term overall benefit although arrhythmic mortality was sig-
nificantly reduced [29, 30].
One may speculate whether outcomes of the two trials 
would have been different if patient randomization would 
have started after a 2- or 3-month WCD prescription period. 
Early post-infarction sudden deaths most likely would have 
been avoided, fewer patients would have received ICDs 
because of subsequently no longer indicated ICD therapy, 
and later on, a true benefit of ICD therapy after myocardial 
infarction with persistent low LVEF could have been elabo-
rated. In addition, the early unpredictable non-arrhythmic 
deaths that may have influenced overall outcomes of the tri-
als could have been censored.
Results of these two trials do not contradict the use of the 
WCD after acute myocardial infarction. They rather request 
risk assessment prior to ICD implantation balancing the risk 
of arrhythmic vs. non-arrhythmic death [31]. The results of the 
DANISH trial stress the ongoing discussion on the true benefit 
of primary prevention ICD therapy in patients with NICM 
[32]. Sudden death was significantly reduced in the ICD group 
without positive impact on overall mortality. Mode of death 
in the ICD group was shifted. DANISH supports the need for 
thorough individualized risk evaluation in patients with vari-
ous forms of NICM [32, 33]. Patients with NICM may have 
an increased risk for ventricular tachyarrhythmia, particularly 
in the early phase with acute heart failure [34–36]. Thus, risk 
assessment under protection of a WCD can be considered.
The recently published VEST trial [14] randomized 
patients with a low LVEF after acute myocardial infarction 
to a WCD arm or no WCD arm. After 3 months, no dif-
ference in arrhythmic deaths between the two groups was 
found, but patients in the WCD group had a significantly 
lower overall mortality. Unfortunately, the VEST trial ended 
after WCD prescription. So, the impact of WCD prescription 
on long-term follow-up remains unclear. The results of the 
VEST trial are not comparable to our registry. They cannot 
be applied to negate the benefit of early post-infarction pro-
tection against sudden arrhythmic death. WCD compliance 
in the VEST trial was very poor (only 14 h per day). In a 
real-world setting, this is unacceptable, as the WCD can only 
terminate VT/VF if properly and permanently worn. This 
low WCD compliance is responsible that only nine out of 
25 patients experiencing sudden death have worn the WCD 
at the time of death. The importance of wear compliance 
was stressed in the recently published as-treated analysis of 
VEST [37]. In addition, the WEARIT-II-EUROPE registry 
is hard to compare with VEST because VEST tried to test 
the WCD as a “therapeutic tool” but not as an approach for 
protected risk stratification after myocardial infarction.
Current guidelines and consensus statements have listed 
prescription of the WCD as a Class IIa or IIb with level of 
evidence C [1, 38]. However, beyond the proven efficacy of 
defibrillation, WEARIT-II-EUROPE showed that the WCD 
represents a promising approach for protected individual risk 
assessment prior to deciding for ICD implantation in patients 
with a presumed but not yet confirmed risk of sudden car-
diac death. Appraisal of patients’ risks of non-arrhythmic 
death or overall mortality regarding long-term benefit of 
defibrillator therapy is the future challenge of sudden cardiac 
death primary prevention. The results of the WEARIT-II-
EUROPE registry support this statement and strengthen the 
request to perform individualized risk assessment prior to 
ICD implantation.
Limitations
WEARIT-II-EUROPE represents the first prospective regis-
try with pre-specified categorized WCD prescriptions testing 
the value of risk assessment under the protecting umbrella 
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of the WCD. The registry protocol did not request specific 
enrollment criteria or had defined exclusion criteria for 
WCD prescription. Treatment, diagnostics and procedures 
during and after WCD prescription were left to physicians’ 
discretion and were not mandated by the registry protocol. 
Thus, the registry represents a real-world scenario. Presum-
ably, follow-up beyond 1 year would have provided addi-
tional information on patients’ long-term outcome. However, 
this would have exceeded our main purpose to analyze LVEF 
development and mortality after WCD prescription. Our 
registry did not aim to evaluate the long-term outcome of 
primary prevention ICD therapy for various underlying dis-
eases. Only 1% of enrolled patients was lost during follow-
up or withdrew from the registry. In seven of the 40 patients, 
the precise cause of death remained undetermined, informa-
tion on ICD implantation could not be recruited in 2% of all 
enrolled patients; however, no death event remained unrec-
ognized. Cost–benefit analysis was not part of the WEARIT-
II-EUROPE registry study protocol. However, a recently 
published cost-effectiveness study of using the WCD early 
after acute myocardial infarction has demonstrated the posi-
tive cost-effectiveness of the WCD and concludes that the 
WCD is economically attractive when compared with other 
generally accepted treatments [39].
Conclusions
In WEARIT-II-EUROPE, the WCD was prescribed for indi-
vidualized risk assessment prior to potentially indicated ICD 
implantation in patients with an early, but possibly not per-
manent risk of sudden arrhythmic death. During the time 
of protected risk assessment, information on improvement 
of left ventricular function and response to medical therapy 
can be gathered and facilitates estimation of patients’ overall 
prognosis. Using the WCD for individualized risk assess-
ment is a promising approach to avoid unnecessary ICD 
implantation and may help increasing the benefit of primary 
preventive ICD therapy.
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